![]() The Zacks Consensus estimate for this segment is pinned at $974 million. Revenues from the International segment are likely to have increased in the third quarter. The Zacks Consensus estimate for this segment is pegged at $1.17 billion. Third-quarter revenues in the United States segment are likely to have increased from the year-ago quarter, based on the rising sales of livestock products and new approvals. The company reports business results under two geographical operating segments - the United States and International. Zoetis’ remaining revenues are derived from its non-pharmaceutical product categories, such as nutritional and agribusiness, and products and services in biodevices, genetic tests and precision animal health. ![]() The veterinary drugmaker derives most of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. Let's see how things might have shaped up in the to-be-reported quarter. Shares of ZTS have gained 11.7% in the year-to-date period against the industry’s 14.3% fall. The company delivered an average earnings surprise of 1.89% in the same time frame. The bottom line surpassed estimates in two of the trailing four quarters, missed in one and met in the other. Zoetis has a mixed earnings surprise history. ![]() ![]() Zoetis Inc. ( ZTS Quick Quote ZTS - Free Report) is scheduled to report third-quarter 2023 results on Nov 2, before market open. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |